Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01)

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01)

Gastrointestinal Stromal Tumor

Recruiting

2

Start Date 09/07/2021

Age of Trial (yrs) 3.2

Neoadjuvant

KIT/PDGFRA inhibitor

Block KIT

Specifically GIST and only GIST

IIT20210023C-R1

First Affiliated Hospital of Zhejiang University

Jiren Yu +8613989879196 yangweili@zju.edu.cn

Oral

Brief Summary
The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was relatively low, and the relapse-free survival rate was relatively low, which needed to be further improved. A few retrospective analyses and a small sample of prospective studies have found that neoadjuvant therapy with imatinib mesylate can improve R0 resection rates. Whether neoadjuvant therapy prolongs long-term survival remains unclear. The primary objective of this study was to evaluate 5-year progression-free survival (PFS) for GIST patients with high recurrence risk after neoadjuvant treatment with imatinib mesylate.